Clozapine and Olanzapine Are Associated With Food Craving and Binge Eating
Authors:
- Michael KlugeMKMichael Kluge
- Andreas SchuldASAndreas Schuld
- Hubertus HimmerichHubertus Himmerich
- Mira DalalMDMira Dalal
- Alexander SchachtASAlexander Schacht
- Peter M. WehmeierPWPeter M. Wehmeier
- Dunja Hinze-SelchDHDunja Hinze-Selch
- Thomas KrausTKThomas Kraus
- Ralf W. DittmannRDRalf W. Dittmann
- Thomas PollmächerTPThomas Pollmächer
- 1 December 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 27 (6) , 662-666
Abstract
The second generation antipsychotics clozapine and olanzapine frequently induce weight gain. Randomized studies investigating abnormal eating behavior (food craving, binge eating) possibly associated with weight gain are lacking. Thirty patients with schizophrenia, schizophreniform, or schizoaffective disorder were included in this randomized, double-blind, parallel study comparing abnormal eating behavior using a standardized scale, clinical efficacy using the Brief Psychiatric Rating Scale0-6 and Clinical Global Impression-Severity scale, and tolerability of clozapine and olanzapine. In both treatment groups, the number of patients reporting food craving, binge eating, or both increased over time. The likelihood to experience food craving at any time during drug treatment showed a trend (P = 0.068) to be higher in the olanzapine group (48.9%) compared with the clozapine group (23.3%). The likelihood to experience binge eating at any time during drug treatment was numerically but not statistically significantly higher in the olanzapine group (16.7%) than in the clozapine group (8.9%). In both groups, significant baseline-to-end point improvements of clinical symptoms (Brief Psychiatric Rating Scale0-6: clozapine, 36.6 ± 8.8 to 15.9 ± 13.7; olanzapine, 36.7 ± 9.9 to 19.1 ± 13.8) and severity of illness (Clinical Global Impression-Severity scale: clozapine, 4.7 ± 0.6 to 2.5 ± 1.5; olanzapine, 4.5 ± 0.6 to 2.3 ± 1.2) were observed. These improvements did not differ significantly between groups. Olanzapine was more tolerable than clozapine; adverse events occurred significantly (P < 0.01) less frequently than in the clozapine group. These results suggest that both clozapine and olanzapine can induce food craving and binge eating, however, olanzapine possibly to a greater extent. Findings on clinical efficacy and safety are in accordance with previous reports.Keywords
This publication has 30 references indexed in Scilit:
- Weight Gain During a Double-Blind Multidosage Clozapine StudyJournal of Clinical Psychopharmacology, 2007
- Health-related quality of life, BMI and physical activity among US adults (⩾18 years): National Physical Activity and Weight Loss Survey, 2002International Journal of Obesity, 2006
- Association of a functional serotonin transporter gene polymorphism with binge eating disorderAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005
- Randomized double blind comparison of olanzapine vs. clozapine on subjective well‐being and clinical outcome in patients with schizophreniaActa Psychiatrica Scandinavica, 2005
- Cerebral D2 and 5-HT2 Receptor occupancy in Schizophrenic Patients Treated with Olanzapine Or ClozapineJournal of Psychopharmacology, 2004
- The Efficacy of High-Dose Olanzapine Versus Clozapine in Treatment-Resistant Schizophrenia: A Double-Blind Crossover StudyJournal of Clinical Psychopharmacology, 2003
- Citalopram in the Treatment of Binge-Eating DisorderThe Journal of Clinical Psychiatry, 2003
- Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective DisorderAmerican Journal of Psychiatry, 2002
- Association of autonomic dysfunction and clozapineThe British Journal of Psychiatry, 2001
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970